Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFSCAR |
Texto Completo: | https://repositorio.ufscar.br/handle/ufscar/17647 |
Resumo: | Chimeric antigen receptor T cell therapy (CAR-T cell therapy) is a type of immunotherapy for cancer treatment that involves genetically modifying the patient's own T cells to express a specific CAR for a tumor antigen, followed by ex vivo cell expansion and reinfusion into the patient. Although CAR-T cells represent a major advance in cancer treatment and have achieved unprecedented success in hematological malignancies, especially in relapsed/refractory B-cell malignancies (R/R), their success in solid tumors is quite limited due to factors such as the highly immunosuppressive tumor microenvironment, low CAR-T cell infiltration, and toxicities. In this systematic review we evaluate the recents CAR-T cells clinical trials tested for different malignancies to overview recent advances in cancer immunotherapy using this approach. We sourced CAPES database, web of science and Pubmed through the following keywords: “Immunotherapy” AND “CAR T cells” and “Solid tumors” AND “CAR T cells”. Some criterions was established to compose this review as the articles had to be published between 2015 and 2021, it must be clinical trials researchers available and published in English language. Review and pre-clinical research articles are both excluded. PRISMA systematic review for clinical trials was consulted and followed to help the discussion and data presentation, and research website, as clinicaltrials.gov and fda.gov, as well as recent pre-clinical improvement CAR T cells were incorporated into the discussion. We obtained 1.188 articles, which 14 met inclusion/exclusion criteria and discussed CAR design, T cell production, and toxicities. Sample size is small but consistent with others reviews. Determinant factors for CAR-T activation and resistance to treatment were identified, including T cell concentration, disease/antigen burden, prior therapies, and CRS/ICANS adverse. Our study has shown that CAR-T cells have a great potential in threatening malignance, even some toxicities may occur. The CAR-T improvement must be continuous to ameliorate the Cell-Associated Neurotoxicity Syndrome/Immune effector Cytokine-Release Syndrome (CRS/ICANS) or even patient’s death, as well as overcome the solid malignance resistance. Several CAR-T cells strategies have been incorporated and developed to reach this goal and successfully has been tested into clinical practice. This evidentiates the high potential of this immunotherapy approach against cancer. |
id |
SCAR_a9079b087b80f0469fd65f98b23b9458 |
---|---|
oai_identifier_str |
oai:repositorio.ufscar.br:ufscar/17647 |
network_acronym_str |
SCAR |
network_name_str |
Repositório Institucional da UFSCAR |
repository_id_str |
4322 |
spelling |
Pereira, Vinicius Alex CanoPranchevicius, Maria Cristina da Silvahttp://lattes.cnpq.br/4772148921558977http://lattes.cnpq.br/063685035179026121e6c3f0-c392-4ef4-bbb6-2ddb3ec3cbc32023-04-06T16:27:58Z2023-04-06T16:27:58Z2023-03-20PEREIRA, Vinicius Alex Cano. Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática. 2023. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) – Universidade Federal de São Carlos, São Carlos, 2023. Disponível em: https://repositorio.ufscar.br/handle/ufscar/17647.https://repositorio.ufscar.br/handle/ufscar/17647Chimeric antigen receptor T cell therapy (CAR-T cell therapy) is a type of immunotherapy for cancer treatment that involves genetically modifying the patient's own T cells to express a specific CAR for a tumor antigen, followed by ex vivo cell expansion and reinfusion into the patient. Although CAR-T cells represent a major advance in cancer treatment and have achieved unprecedented success in hematological malignancies, especially in relapsed/refractory B-cell malignancies (R/R), their success in solid tumors is quite limited due to factors such as the highly immunosuppressive tumor microenvironment, low CAR-T cell infiltration, and toxicities. In this systematic review we evaluate the recents CAR-T cells clinical trials tested for different malignancies to overview recent advances in cancer immunotherapy using this approach. We sourced CAPES database, web of science and Pubmed through the following keywords: “Immunotherapy” AND “CAR T cells” and “Solid tumors” AND “CAR T cells”. Some criterions was established to compose this review as the articles had to be published between 2015 and 2021, it must be clinical trials researchers available and published in English language. Review and pre-clinical research articles are both excluded. PRISMA systematic review for clinical trials was consulted and followed to help the discussion and data presentation, and research website, as clinicaltrials.gov and fda.gov, as well as recent pre-clinical improvement CAR T cells were incorporated into the discussion. We obtained 1.188 articles, which 14 met inclusion/exclusion criteria and discussed CAR design, T cell production, and toxicities. Sample size is small but consistent with others reviews. Determinant factors for CAR-T activation and resistance to treatment were identified, including T cell concentration, disease/antigen burden, prior therapies, and CRS/ICANS adverse. Our study has shown that CAR-T cells have a great potential in threatening malignance, even some toxicities may occur. The CAR-T improvement must be continuous to ameliorate the Cell-Associated Neurotoxicity Syndrome/Immune effector Cytokine-Release Syndrome (CRS/ICANS) or even patient’s death, as well as overcome the solid malignance resistance. Several CAR-T cells strategies have been incorporated and developed to reach this goal and successfully has been tested into clinical practice. This evidentiates the high potential of this immunotherapy approach against cancer.A terapia com células T do receptor de antígeno quimérico (CAR-T cells) é um tipo de tratamento imunoterápico contra o câncer, que envolve a modificação genética das células T autólogas do paciente para expressar um CAR específico para um antígeno tumoral, seguido de expansão celular ex vivo e reinfusão de volta ao paciente. Embora as CAR-Ts represente um grande avanço no tratamento do câncer e alcançou um sucesso sem precedentes em malignidades hematológicas, especialmente em malignidades de células B recidivantes/refratárias (R/R), seu sucesso em tumores sólidos é bastante limitante devido a fatores como o microambiente tumoral altamente imunossupressor, baixa infiltração das CAR-Ts, toxicidades. Nesta revisão sistemática, avaliamos testes clínicos de CAR-Ts para diferentes tumores com o objetivo de analisar os recentes avanços nesse tipo de tratamento. Foram consultados bancos de dados como CAPES database, web of Science e Pubmed através de palavras-chaves como “Immunotherapy” AND “CAR T cells” e “Solid tumors” AND “CAR T cells”. Alguns critérios de inclusão foram estabelecidos como: a publicação dos artigos deveria ser entre os anos 2015-2021, e deveriam ser pesquisas clínicas disponíveis e publicadas em inglês. Critérios para não-inclusão consistiam em artigos de revisão e testes pré-clínicos. PRISMA systematic review for clinical trials foi utilizado para implementar a escrita do presente trabalho, os sites do clinicaltrials.gov e fda.gov auxiliaram nas análises relacionadas aos aprimoramentos de células CAR-T. Um total de 1.188 artigos foram obtidos, nos quais 14 contemplaram os critérios de inclusão e serviram como base para as análises da efetividade, segurança e limitações das CAR T-cells. Embora o número amostral apresentou-se pequeno, manteve-se coerente com o observado na literatura científica. Fatores críticos para ativação das CAR-Ts e resistência ao tratamento foram identificados, incluindo concentração de células T, carga de doença/antígeno, terapias anteriores e efeitos Cytokine-Release Syndrome/Immune effector Cell-Associated Neurotoxicity Syndrome (CRS/ICANS). O aprimoramento das CAR-Ts é de fundamental importância para amenizar os efeitos CRS/ICANS, evitar a morte do paciente, e sobrepor os desafios apresentados no tratamento de tumores sólidos. Uma ampla variedade de estratégias para células CAR-Ts tem sido desenvolvida e incorporada para atingir esses objetivos e, com sucesso, vem sendo testadas na prática clínica. O presente estudo reitera o grande potencial das células CAR-Ts no tratamento de tumores, mesmo com a ocorrência de algumas limitações.Não recebi financiamentoporUniversidade Federal de São CarlosCâmpus São CarlosBiotecnologia - BiotecUFSCarAttribution-NonCommercial-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nc-nd/3.0/br/info:eu-repo/semantics/openAccessTumorsImmunotherapyCAR-TTumoresImunoterapiaCIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA APLICADACIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA CELULARImunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemáticaClinical immunotherapy with CAR T cells used against tumors - a systematic reviewinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesis600600e3562ea5-a37d-4363-86a4-8b169b388e13reponame:Repositório Institucional da UFSCARinstname:Universidade Federal de São Carlos (UFSCAR)instacron:UFSCARORIGINALTCC_ViniciusAlexCanoPereira_repositório.pdfTCC_ViniciusAlexCanoPereira_repositório.pdfTCC do aluno Vinicius Alex Cano Pereira. Curso de Biotecnologia. UFSCar-Campus São Carlosapplication/pdf1633810https://repositorio.ufscar.br/bitstream/ufscar/17647/1/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf67d0c97e5a760788441b4e531c7ec595MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8810https://repositorio.ufscar.br/bitstream/ufscar/17647/2/license_rdff337d95da1fce0a22c77480e5e9a7aecMD52TEXTTCC_ViniciusAlexCanoPereira_repositório.pdf.txtTCC_ViniciusAlexCanoPereira_repositório.pdf.txtExtracted texttext/plain158718https://repositorio.ufscar.br/bitstream/ufscar/17647/3/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf.txt7c47e7b0b2b528173618006614d3d506MD53THUMBNAILTCC_ViniciusAlexCanoPereira_repositório.pdf.jpgTCC_ViniciusAlexCanoPereira_repositório.pdf.jpgIM Thumbnailimage/jpeg5159https://repositorio.ufscar.br/bitstream/ufscar/17647/4/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf.jpgb3ac5890c3479f7847bcbd2c66735c46MD54ufscar/176472023-09-18 18:32:35.619oai:repositorio.ufscar.br:ufscar/17647Repositório InstitucionalPUBhttps://repositorio.ufscar.br/oai/requestopendoar:43222023-09-18T18:32:35Repositório Institucional da UFSCAR - Universidade Federal de São Carlos (UFSCAR)false |
dc.title.por.fl_str_mv |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
dc.title.alternative.eng.fl_str_mv |
Clinical immunotherapy with CAR T cells used against tumors - a systematic review |
title |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
spellingShingle |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática Pereira, Vinicius Alex Cano Tumors Immunotherapy CAR-T Tumores Imunoterapia CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA APLICADA CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA CELULAR |
title_short |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
title_full |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
title_fullStr |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
title_full_unstemmed |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
title_sort |
Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática |
author |
Pereira, Vinicius Alex Cano |
author_facet |
Pereira, Vinicius Alex Cano |
author_role |
author |
dc.contributor.authorlattes.por.fl_str_mv |
http://lattes.cnpq.br/0636850351790261 |
dc.contributor.author.fl_str_mv |
Pereira, Vinicius Alex Cano |
dc.contributor.advisor1.fl_str_mv |
Pranchevicius, Maria Cristina da Silva |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/4772148921558977 |
dc.contributor.authorID.fl_str_mv |
21e6c3f0-c392-4ef4-bbb6-2ddb3ec3cbc3 |
contributor_str_mv |
Pranchevicius, Maria Cristina da Silva |
dc.subject.eng.fl_str_mv |
Tumors Immunotherapy |
topic |
Tumors Immunotherapy CAR-T Tumores Imunoterapia CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA APLICADA CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA CELULAR |
dc.subject.por.fl_str_mv |
CAR-T Tumores Imunoterapia |
dc.subject.cnpq.fl_str_mv |
CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA APLICADA CIENCIAS BIOLOGICAS::IMUNOLOGIA::IMUNOLOGIA CELULAR |
description |
Chimeric antigen receptor T cell therapy (CAR-T cell therapy) is a type of immunotherapy for cancer treatment that involves genetically modifying the patient's own T cells to express a specific CAR for a tumor antigen, followed by ex vivo cell expansion and reinfusion into the patient. Although CAR-T cells represent a major advance in cancer treatment and have achieved unprecedented success in hematological malignancies, especially in relapsed/refractory B-cell malignancies (R/R), their success in solid tumors is quite limited due to factors such as the highly immunosuppressive tumor microenvironment, low CAR-T cell infiltration, and toxicities. In this systematic review we evaluate the recents CAR-T cells clinical trials tested for different malignancies to overview recent advances in cancer immunotherapy using this approach. We sourced CAPES database, web of science and Pubmed through the following keywords: “Immunotherapy” AND “CAR T cells” and “Solid tumors” AND “CAR T cells”. Some criterions was established to compose this review as the articles had to be published between 2015 and 2021, it must be clinical trials researchers available and published in English language. Review and pre-clinical research articles are both excluded. PRISMA systematic review for clinical trials was consulted and followed to help the discussion and data presentation, and research website, as clinicaltrials.gov and fda.gov, as well as recent pre-clinical improvement CAR T cells were incorporated into the discussion. We obtained 1.188 articles, which 14 met inclusion/exclusion criteria and discussed CAR design, T cell production, and toxicities. Sample size is small but consistent with others reviews. Determinant factors for CAR-T activation and resistance to treatment were identified, including T cell concentration, disease/antigen burden, prior therapies, and CRS/ICANS adverse. Our study has shown that CAR-T cells have a great potential in threatening malignance, even some toxicities may occur. The CAR-T improvement must be continuous to ameliorate the Cell-Associated Neurotoxicity Syndrome/Immune effector Cytokine-Release Syndrome (CRS/ICANS) or even patient’s death, as well as overcome the solid malignance resistance. Several CAR-T cells strategies have been incorporated and developed to reach this goal and successfully has been tested into clinical practice. This evidentiates the high potential of this immunotherapy approach against cancer. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-04-06T16:27:58Z |
dc.date.available.fl_str_mv |
2023-04-06T16:27:58Z |
dc.date.issued.fl_str_mv |
2023-03-20 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
PEREIRA, Vinicius Alex Cano. Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática. 2023. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) – Universidade Federal de São Carlos, São Carlos, 2023. Disponível em: https://repositorio.ufscar.br/handle/ufscar/17647. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufscar.br/handle/ufscar/17647 |
identifier_str_mv |
PEREIRA, Vinicius Alex Cano. Imunoterapia clínica de células CAR-T usadas contra tumores – uma revisão sistemática. 2023. Trabalho de Conclusão de Curso (Graduação em Biotecnologia) – Universidade Federal de São Carlos, São Carlos, 2023. Disponível em: https://repositorio.ufscar.br/handle/ufscar/17647. |
url |
https://repositorio.ufscar.br/handle/ufscar/17647 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.confidence.fl_str_mv |
600 600 |
dc.relation.authority.fl_str_mv |
e3562ea5-a37d-4363-86a4-8b169b388e13 |
dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nc-nd/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nc-nd/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal de São Carlos Câmpus São Carlos Biotecnologia - Biotec |
dc.publisher.initials.fl_str_mv |
UFSCar |
publisher.none.fl_str_mv |
Universidade Federal de São Carlos Câmpus São Carlos Biotecnologia - Biotec |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFSCAR instname:Universidade Federal de São Carlos (UFSCAR) instacron:UFSCAR |
instname_str |
Universidade Federal de São Carlos (UFSCAR) |
instacron_str |
UFSCAR |
institution |
UFSCAR |
reponame_str |
Repositório Institucional da UFSCAR |
collection |
Repositório Institucional da UFSCAR |
bitstream.url.fl_str_mv |
https://repositorio.ufscar.br/bitstream/ufscar/17647/1/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf https://repositorio.ufscar.br/bitstream/ufscar/17647/2/license_rdf https://repositorio.ufscar.br/bitstream/ufscar/17647/3/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf.txt https://repositorio.ufscar.br/bitstream/ufscar/17647/4/TCC_ViniciusAlexCanoPereira_reposito%cc%81rio.pdf.jpg |
bitstream.checksum.fl_str_mv |
67d0c97e5a760788441b4e531c7ec595 f337d95da1fce0a22c77480e5e9a7aec 7c47e7b0b2b528173618006614d3d506 b3ac5890c3479f7847bcbd2c66735c46 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFSCAR - Universidade Federal de São Carlos (UFSCAR) |
repository.mail.fl_str_mv |
|
_version_ |
1802136419513139200 |